| Literature DB >> 33328984 |
Chun-Ting Lee1,2, Keng-Shiang Huang1, Jei-Fu Shaw3, Jung-Ren Chen3, Wen-Shuo Kuo4, Gangxu Shen1, Alexandru Mihai Grumezescu5, Alina Maria Holban6, Yi-Ting Wang3, Jun-Sheng Wang7, Yi-Ping Hsiang8, Yu-Mei Lin1,3, Hsiao-Han Hsu2, Chih-Hui Yang3,7,8.
Abstract
Cordyceps militaris (C. militaris) is a fungus with a long history of widespread use in folk medicine, and its biological and medicinal functions are well studied. A crucial pharmacological effect of C. militaris is immunomodulation. In this review, we catalog the immunomodulatory effects of different extracts of C. militaris, namely total extracts, polysaccharides and cordycepin. Total extracts obtained using water or 50% ethyl alcohol and polysaccharides from C. militaris were discovered to tend to promote type 1 immunity, whereas total extracts obtained using 70-80% ethyl alcohol and cordycepin from C. militaris were more likely to promote type 2 immunity. This article is the first to classify the immunomodulatory effects of different extracts of C. militaris. In addition, we discovered a relationship between different segments or extracts and differing types of immunity. This review can provide the readers a comprehensive understanding on the immunomodulatory effects of the precious folk medicine and guidance on its use for both health people and those with an immunodeficiency.Entities:
Keywords: Cordyceps militaris; cordycepin; immunomodulation; polysaccharides; type 1 immunity; type 2 immunity
Year: 2020 PMID: 33328984 PMCID: PMC7735063 DOI: 10.3389/fphar.2020.575704
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
FIGURE 1(A) The dried fruiting body products of C. militaris (B) The cultured mycelia of C. militaris.
Summary of the biological activities of C. militaris.
| Title | Brief descriptions | References |
|---|---|---|
| Biotechnological production and applications of | 1. Antibacteria, antiinflammation, antiplatelet aggregation, antihyperlipidemic and antitumor activities were found in cordycepin | ( |
| 2. Chronic heart failure, immunomodulatory effect, sleep-wake regulation, vessels tone regulation, antidepressant, anticonvulsant, amnesic and anxiolytic activities were found in adenosine derivatives | ||
| 3. Antiviral effect, antitumor, immunomodulation, antioxidative and antiaging activities were found in polysaccharide | ||
| 4. Antiviral, antiarrhythmic and blocking the activated human mesangial cells activities were found in ergosterol analogs | ||
| 5. Diuretic, antitussive and anti-free radical activities were found in mannitol | ||
| 6. Antitumor, immunomodulation and antifungal effects were found in peptides | ||
| 7. Antithrombosis effect was found in fibrinolytic enzyme | ||
| 8. Antitumor effect was found in xanthophylls | ||
| Pharmacological actions of | 1. Antiinflammatory effect was found in polysaccharides | ( |
| 2. Antioxidant, inhibiting tumor growth and antiangiogenesis, reducing hyperglycemia and inhibiting low-density lipoprotein-induced glomerulosclerosis activities were found in water extract of | ||
| Medicinal uses of the mushroom | 1. Improved sperm production, modulated immune response, prevented oxidation, antitumor activity, antimicrobial activity, insecticidal activity, larvicidal activity, antifibrotic effect, hypoglycemic effect, antihyperlipidemic effect, antiangiogenesis activity, antidiabetic effect, antifatigue activity, neuroprotection, liver protection, renoprotection and pneumo-protection activities were found | ( |
|
| 1. Antitumor effect, inducing dendritic cells maturation, increasing IL-18 gene expression, improving insulin resistant and insulin secretion and increase physical strength were found in aqueous extract of | ( |
| 2. Antiinflammation effect, improved and restored impaired reproductive function and renal protection were demonstrated by direct administration of | ||
| The genus | 1. Immunomodulatory function, antitumor activity, nephroprotective activity, hepatoprotective activity, neuroprotective effect, antioxidative effect, antimicrobial effect, insecticidal activity, antifibrotic effect and hypoglycemic activity were found | ( |
FIGURE 2The biological activities of C. militaris. 3′-deoxyadenosine (cordycepin), adenosine derivatives, polysaccharides, ergosterol analogs, mannitol, peptides, fibrinolytic enzyme, xanthophylls, aqueous or alcohol extracts, and the powders of C. militaris have exhibited specific biological activities. The immunoregulation is one of the important functions of C. militaris. Immune response has been divided into type 1 and type 2, the balance between these two types of immunity is crucial to our health.
FIGURE 3The difference between type 1 immunity and type 2 immunity. Type 1 immunity is related to cytotoxic functions and type 2 immunity is related to immunosuppressive function or inflammatory functions of cytokine IL-4, IL-5 and IL-13. In nowadays, type 1 immunity is associated with tumor and intracellular pathogens killing and type 2 immunity is associated with extracellular parasite eradiation and tissue repair, except fibrosis.
The immunomodulation effects of total plant extracts from C. militaris.
| Origin | Extracting Method | Function and Possible Mechanism | References |
|---|---|---|---|
| Fruiting body extract and cultured mycelia extract | 70% ethanol at room temperature | 1. Inflammation ↓ (fruiting bodies extract ≈ cultured mycelia extract) ↑ | ( |
| 2. iNOS expression ↓ (fruiting bodies extract ≈ cultured mycelia extract) | — | ||
| 3. Angiogenesis ↓ (cultured mycelia extract > fruiting bodies extract) | — | ||
| Fruiting body extract | Distilled water and then boiled for 4 h | 1. IL-18 ↑ expression in mice brain and liver tissue | ( |
| 2. IL18 ↑ and INF- | |||
| Fruiting body extract | Distilled water and then boiled for 30 min | In OVA-induced asthma mice | ( |
| 1. Serum IgE↓ in OVA-induced asthma mice | |||
| 2. Infiltrated inflammatory cells↓ and thickening of smooth muscle layer in airway ↓ | |||
| Fruiting body extract | Distilled water and 60 °C for 6 h | ● macrophage activity modulation | ( |
| 1. Macrophage proinflammatory cytokine ↑ (such as IL-1 | |||
| 2. B7-1/-2 and ICAM-1 expression ↑ | |||
| 3. Might be related to NF- | |||
| ● dendritic cells activity modulation | |||
| 1. | |||
| 2. | |||
| 3. Inflammatory cytokine expression ↑ (such as IL-1 | |||
| 4. Might be related to NF- | |||
| Mycelium extract | Distilled water and then boiled for 48 h | ● in dextran sodium sulfate-induced acute colitis mice model | ( |
| 1. Reducing body weight loss, diarrhea and gross bleeding | |||
| 2. Preventing shortening of colon length and crypt length | |||
| 3. Suppressing epithelial damage, loss of goblet cells, loss of crypts and infiltration of inflammatory cells | |||
| 4. iNOS and TNF- | |||
| 5. Mast cells degranulation ↓ in colon tissue | |||
| ● in cell line model | |||
| 1. iNOS and TNF- | |||
| 2. Degranulation of antigen-stimulated mast cells ↓ | |||
| Mycelium extract | The total extract was dissolved with water, after remove the insoluble solid by filtration, the liquid phase was extracted by hexane, ethyl acetate, or tert-butyl alcohol | 1. Degranulation of antigen-induced mast cells ↓ | ( |
| 2. Reduction passive cutaneous anaphylaxis reaction in antigen-induced mice model | |||
| 3. The antiallergic effects might be associated with lowing the expression level of the phosphorylation syk, ERK, p38 and JNK. | |||
| Fresh | With water and the mixture was homogenated at 4,000 r/min for 15 min, then treated with ultrasonic waves at 30°C for 30 min | 1. Reversing the reduction of spleen and thymus index induced by cy (fresh | ( |
| 2. Increasing the phagocytotic effect in cy-induced mice (fresh | |||
| 3. Recovering the IL-2 and IFN- | |||
| 4. The chemical composition polysaccharides, total polyphenol and total flavonoids were greater in fresh | |||
|
| Provided by dong-a pharm. Co., LTD. (korea) | ● in health mice | ( |
| IL-12 ↑ in plasma and NK cells population ↑ in peripheral blood | |||
| ● in H1N1 infected mice model | |||
| 1. mortality ↓ | |||
| 2. IL-12 ↑ and TNF- | |||
| Dried | 50% ethanol at room temperature and at normal pressure for 3 days | 1. IL-2 ↑ and IFN-γ ↑ | ( |
| 2. Enhancing NK cells activity and T-cell proliferation | |||
|
| 80% EtOH for 48 h twice | ● in DNFB-induced contact dermatitis mice model | ( |
| 1. Ear swelling ↓ | |||
| 2. Reducing T cells infiltrated ↓ (including CD4 and CD8) | |||
| ● in concanavalin-A stimulated T cells proliferation model | |||
| 1. T cells proliferation ↓ | |||
| Fruiting body extract | Distilled water at 65°C for 2 h (pH 6.5) | 1. Increasing thymus and spleen index | ( |
| 2. Total white blood cell count were increased (lymphocytes ↑; monocytes ↑; neutrophils ↓; eosinophils and basophils no changed) | |||
| 3. Increasing IgG content | |||
| 4. Increasing TNF- | |||
| 5. Increasing the activity of superoxidase dismutase, glutathione peroxidase, and total antioxidant capacity activity in liver, kidney and heart tissue; MDA level were decreased in liver, kidney, heart and serum sample |
The immunomodulation effects of polysaccharides from C. militaris.
| Name | Size and Structural Content | Function and Possible Mechanism | References |
|---|---|---|---|
| CPS-1 | 1. MW = 2.3 × 104 Da | 1. Reduced inflammation | ( |
| 2. Content: Rha, Xyl, D-Man, D-Glc and D-Gla in a ratio of 1:6.43:25.6:16.0:13.8 | 2. Modulate humoral immunity | ||
| 3. Structure: Mannose bonded by (1→2) linkage, xylose bonded by (1→4) linkage, and rhamnose bonded with galactose by (1→2) or (1→3) linkage | 3. No effect on phagocytotic function on innate immunity | ||
| 4. No effect on cellular immunity | |||
| Cordlan | 1. MW = 5.76 × 105 Da |
| ( |
| 2. Content: D-gal, ara, Xyl and rha in a ratio of 9.11:4.34:1.17:1 | 1. Prevent influenza a virus infected mice from death | ||
| 3. Structure: Ara | 2. Increase inflammatory cytokine (IL-1 | ||
| 3. Increase antiinflammatory cytokine (IL-10) expression which might prevent macrophage excessive activation | |||
|
| |||
| 1. Elevating the mature DC phenotypic markers such as CD40, CD80, CD86, MHC-I, and MHC-II molecules and mature DC functional marker such as IL-12, IL-1 | |||
| 2. Induce immature dendrtic cells into mature dendrtic cells through TLR4 pathway | |||
| Cordysinocan | 1. MW = 8.2 × 104 Da | 1. Enhancing T lymphocytes proliferation and IL-2 secretion | ( |
| 2. Content: D-Glc, D-Man and D-Gal in a ratio of 2.4:2:1 | 2. Promoting macrophage phagocytotic and acid phosphatase activities | ||
| 3. Structure: Not available | — | ||
| CPSN Fr II | 1. MW = 3.6 × 104 Da | 1. Elevating TNF- | ( |
| 2. Content: D-Man, D-Gal and D-Glc in a ratio of 10.64:4.69:1; proteins, hexosamine and uronic acid of this polysaccharide are 0.20, 0.06 and 0.29%, respectively | 2. Increasing nitric oxide production in macrophage | ||
| 3. Structure: The backbone of (1→2)-linked | 3. The macrophage activation might be associated with MAPKs and NF | ||
| CPMN Fr III | 1. MW = 2.1 × 105 Da | 1. Elevating TNF- | ( |
| 2. Content: D-Man, D-Gal and D-Glc in a ratio of 7.88:2.03:1; proteins, hexosamine and uronic acid of this polysaccharide are 0.21, 0.12 and 0.33%, respectively | 2. Increasing nitric oxide production in macrophage | ||
| 3. Structure: The backbone of (1→6)-linked | |||
| Polysaccharides (CM) | 1. MW = 1.27 × 105 Da | 1. Elevating the expression of ROS, nitric oxide, TNF- | ( |
| 2. Content: Not available | 2. The immune modulation effects might be associated with NF- | ||
| 3. Structure: (1→4) or (1→2) linked | 3. Antitumor effect by regulating host immune response but not killing the tumor cells directly | ||
| Polysaccharides (CMP) | 1. MW = not available | 1. Reversing the decreasing of spleen and thymus indices in cy-injected mice | ( |
| 2. Content: Not available | 2. Increasing the lymphocyte proliferation in cy-injected mice | ||
| 3. Structure: Not available | 3. Recovered the phagocytotic index in cy-injected mice | ||
| 4. Improving the antioxidative ability in cy-injected mice | |||
| CMP-W1 | CMP-W1 | 1. Inducing mice splenocytes proliferation | ( |
| 1. MW = 3.66 × 105 Da | 2. With synergistical effect on concanavalin-A induced T-cells proliferation | ||
| 2. Content: D-Man: D-Glc: D-Gal with the molar ratios of 2.84:1:1.29 | 3. With synergistical effect on LPS induced B-cells proliferation | ||
| 3. Structure: Not available | — | ||
| CMP-S1 | CMP-S1 | ||
| 1. MW = 4.6 × 105 Da | |||
| 2. Content: D-Man: D-Glc: D-Gal with the molar ratios of 2.05:1:1.09 | |||
| 3. Structure: Not available | |||
| CMP-III | 1. MW = 4.796 × 107 Da | 1. Enhancing macrophage phagocytosis ability | ( |
| 2. Content: D-Glc: D-Man: D-Gal with the molar ratio of 8.09:1:0.25 | 2. Increasing TNF-α, IL-6 and NO secretion | ||
| 3. Structure: 1→4)-α-D-Glc (70.08%), 1→4,6)-α-D-Man (9.59%), 1→)-α-D-Man (10.79%) and 1→2,6)-α-D-Gal (3.93%) | |||
| CMPB90–1 | 1. MW = 5.8 × 103 Da | 1. Converting M2 macrophage into M1-like which could increase our body to eradicate tumor | ( |
| 2. Content: D-Gal: D-Glc: D-Man with the molar ratios of 3.04:1:1.45 | 2. Increasing T cells activity by inhibiting the PD-L1/PD-1 axis between tumor associated macrophage and T cells | — | |
| 3. Structure: (1→6)-α- | — | — |
The immunomodulation effects of cordycepin.
| Dosage | Model | Function and Possible Mechanism | References |
|---|---|---|---|
| 5, 10, 15, 30 μg/ml | LPS-induced RAW 264.7 macrophage | 1. Inhibiting iNOS, COX-2 and TNF- | ( |
| 2. The inhibition effect might be associated with suppression of NF- | |||
| 5, 10, 20, 40 μg/ml | LPS-induced RAW 264.7 macrophage | 1. Decreasing TNF- | ( |
| 2. Reducing T2D associated genes expression, such as RANTES, 11 | |||
| 3. Co-stimulatory molecule B7-1/-2 and ICAM-1 were reduced | |||
| 4. The anti-inflammatory and anti-diabetic effects might be related to NF- | |||
| 5, 10, 20, 40 μg/ml | LPS-induced RAW 264.7 macrophage | 1. Decreasing M1 cytokines such as IL-1 | ( |
| 2. M2 cytokine such as IL-1ra, IL-10 and TGF- | |||
| 1, 2.5, 5, 7.5 μg/ml | LPS-induced BV2 microglia | 1. Reducing iNOS and COX-2 expression that result in decreasing the level of nitric oxide and PGE2 | ( |
| 2. Decreasing the secretion level of TNF- | |||
| 3. The inhibition of immune response might be associated with NF- | |||
| 10, 50, 100, 200 μg/ml | TNF- | 1. Reducing IKK | ( |
| 2. IKK | |||
| 3. Reducing the activity of IKK | |||
| 4. Presence lots of I | |||
| 10, 20, 40 μg/ml | Concanavalin A-induced T cells and DNFB-induced delayed-type hypersensitivity reaction | 1. Decreasing concanavalin A-induced T cells proliferation | ( |
| 2. Reducing both Th1 (IL-2 and IFN- | |||
| 3. Abolishing the DNFB-induced delayed-type hypersensitivity reaction | |||
| 4. The T cells suppression might be associated with NFAT2 signaling pathway | |||
| 10, 20, 30 μg/ml | LPS-induced RAW 264.7 macrophage | 1. Reducing COX-2 and iNOS expression | ( |
| 2. Decreasing the expression of IL-1 | |||
| 3. P65 expression decreased in nucleus and I | |||
| 4. Suppression of MAPKs activity | |||
| 5. Abolishing the expression of LPS-induced TLR4 and MyD88 | |||
| 10, 20, 40 mg/kg | OVA-induced murine model | 1. Reducing serum IgE level and BAL fluid eotaxin, ICAM-1 and Th2 cytokine | ( |
| 2. Decreasing infiltrated cells in BAL fluid, including eosinophils, neutrophils, macrophages and lymphocytes | |||
| 3. Suppression the airway inflammation and mucus secretion | |||
| 4. The mechanism might be associated with p38-MAPK and NF- | |||
| 1, 5, 10, 20 mg/kg | Traumatic brain injury rat model | 1. Neurological severity score, brain infarction volume and brain water content were significantly reduced | ( |
| 2. ZO-1 and occludin were restored | |||
| 3. IL-1 | |||
| 0.1, 1 or 10 µM | TSLP-induced HMC-1 human mast cell | 1. Reducing IL-6, TNF- | ( |
| 2. Decreasing pSTAT6 expression and cells proliferation | |||
| 3. Down-regulating murine double minute 2 and Bcl-2 expression and up-regulating p53, caspase 3 and cleaved poly ADP-ribose polymerase levels | |||
| 50 mg/kg | With or without budesonide treated OVA-induced asthma rat model | 1. Reducing the cytokine IL-5, IL-13 and TNF- | ( |
| 2. Reducing the thickness of bronchial wall | |||
| 3. Up-regulating adenosine A2A receptor and down-regulating p38 MAPK in cordycepin with or without budesonide group but not in budesonide alone group | |||
| 3 mg/kg, 5 mg/kg and 12.5 mg/kg | CD-1 mice with anxiety-like behaviors using elevated plus maze or light-dark box tests | 1. Reducing mice anxiety | ( |
| 2. Increasing IL-4 and IL-13 expression | |||
| 3. Reducing TNF-α and IL-1β | |||
| 2 mg/kg, 10 mg/kg and 20 mg/kg | CFA induced paw edema | 1. Reducing T cell activity and T cell proliferation | ( |
| 2. Decreasing IL-2 expression | |||
| 3. Inhibiting TCR signaling cascade(by reducing ZAP70 and erk phosphorylation) |
FIGURE 4Immunomodulatory effects from different ingredients of C. militaris. In normal condition, host immune system always reach the balance of type 1 immunity and type 2 immunity. When the balance is broken, the host might suffer from the disease.